Virax files prostate cancer therapy patent
02 July, 2002 by Tanya HollisImmune-based drug developer Virax Holdings has announced it had filed a patent relating to a potential new prostate cancer therapy.
GTG claims progress made in AIDS research
02 July, 2002 by Melissa TrudingerMelbourne company Genetic Technologies has reported that it is making good progress with its AIDS research project.
Peptech seeks approval for dog contraceptive
02 July, 2002 by Tanya HollisPeptech's animal health division has applied to register its medication to control fertility and reproductive behaviour in dogs.
Peplin overcomes scale-up hurdles and exports cancer drug
02 July, 2002 by Pete YoungPeplin Biotech has shipped the first significant quantity of its lead anti-cancer drug PEP 005 after a year-long effort which it says has "cracked the back" of any manufacturing problems.
Acrux raises $9.8m to speed drug delivery program
02 July, 2002 by Tanya HollisNovel drug delivery company Acrux has raised $9.8 million through the sale of 10 per cent of its stock to Queensland Investment Corporation.
Eiffel signs new drug delivery agreement
01 July, 2002 by Tanya HollisEiffel Technologies has signed a new agreement with specialist UK drug company Profile Therapeutics to investigate delivery methods for an undisclosed pharmaceutical compound.
Canola pollen travels... but doesn't do much when it arrives
01 July, 2002 by Melissa TrudingerPollen from a herbicide-tolerant canola crop spreads to neighbouring fields, according to Australian study published in the June 28th issue of Science, but only a very low percentage of plants are fertilised there.
Varian to open HPLC production facility in Melbourne
28 June, 2002 by Tanya HollisVictoria has won a key investment in a $US200 million coup that sees a Silicon Valley production facility shift its base to Melbourne's east.
Xcell appoints regulatory team for US, Europe push
27 June, 2002 by Tanya HollisPerth-based devices group Xcell Diagnostics has gathered up a specialised regulatory affairs team to drive United States and European registration of its Funhaler product.
GM sensitivities force caution on biotech R&D
27 June, 2002 by Pete YoungConsumer sensitivities over genetically modified foods are forcing biotech researchers in Australia's sugar industry to walk a tightrope.
Cochlear implant upgrades should be free: Labor MP
26 June, 2002 by Tanya HollisHearing impaired Australians should have access to free cochlear implant processor upgrades, according to a Labor MP.
New respiratory medicine exchange program
25 June, 2002 by Melissa TrudingerA million-dollar grant from GlaxoSmithKline has allowed the Institute of Respiratory Medicine to set up a scientist exchange program to allow Australian scientists to travel and work overseas and to bring international scientists to work at the institute.
AIMS solves mystery poison puzzle
25 June, 2002 by Melissa TrudingerAn Australian researcher at the Australian Institute of Marine Science (AIMS) has solved the medical mystery of the death of an East Timorese man from what appeared to be poisoning in late 2000.
R&D Start freeze could shelve cancer project
24 June, 2002 by Tanya HollisA Western Australian research project into the use of carotenoids as a treatment for prostate cancer has been shelved because of the halt to the Federal government's R&D Start program.
Mandatory food labelling, testing laws unworkable: ANZFA
24 June, 2002 by Tanya HollisMandatory, industry-wide food labelling laws would be unworkable and create huge costs for businesses and consumers, according to Australia's peak food authority.
